Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urethral Obstruction | 2 | 2021 | 8 | 1.550 |
Why?
|
| Urethra | 5 | 2021 | 56 | 1.290 |
Why?
|
| Arthritis, Rheumatoid | 13 | 2014 | 155 | 1.050 |
Why?
|
| Urinary Catheterization | 1 | 2021 | 27 | 0.760 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 72 | 0.750 |
Why?
|
| Preoperative Care | 1 | 2021 | 275 | 0.660 |
Why?
|
| Endoscopy | 1 | 2021 | 464 | 0.590 |
Why?
|
| Hypospadias | 2 | 2013 | 3 | 0.420 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2010 | 11 | 0.360 |
Why?
|
| Urinary Incontinence | 1 | 2010 | 67 | 0.350 |
Why?
|
| Surgical Flaps | 1 | 2010 | 120 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2010 | 627 | 0.310 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 20 | 0.300 |
Why?
|
| Infant, Newborn | 4 | 2021 | 2455 | 0.300 |
Why?
|
| Scleroderma, Systemic | 6 | 2008 | 446 | 0.290 |
Why?
|
| Intestine, Small | 1 | 2007 | 89 | 0.290 |
Why?
|
| Twins, Monozygotic | 1 | 2004 | 27 | 0.240 |
Why?
|
| Male | 27 | 2021 | 37283 | 0.240 |
Why?
|
| Tuberous Sclerosis | 1 | 2002 | 13 | 0.210 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 110 | 0.200 |
Why?
|
| Collagen Type I | 3 | 2008 | 175 | 0.200 |
Why?
|
| Kidney | 2 | 2014 | 945 | 0.190 |
Why?
|
| Humans | 35 | 2021 | 68549 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 206 | 0.190 |
Why?
|
| Catheters | 1 | 2021 | 39 | 0.190 |
Why?
|
| Ablation Techniques | 1 | 2021 | 33 | 0.190 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2014 | 13 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2013 | 1851 | 0.150 |
Why?
|
| Osteoporosis | 2 | 2010 | 88 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 2 | 2010 | 47 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2021 | 7268 | 0.140 |
Why?
|
| Alleles | 4 | 2010 | 386 | 0.140 |
Why?
|
| Urography | 1 | 2016 | 21 | 0.140 |
Why?
|
| Prune Belly Syndrome | 1 | 2016 | 5 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7028 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 514 | 0.120 |
Why?
|
| Collagen | 4 | 2008 | 636 | 0.120 |
Why?
|
| Female | 21 | 2014 | 38021 | 0.120 |
Why?
|
| Wrist Joint | 2 | 2010 | 15 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2014 | 43 | 0.110 |
Why?
|
| Fibroblasts | 4 | 2008 | 902 | 0.110 |
Why?
|
| Hand | 2 | 2010 | 90 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2013 | 1615 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2014 | 285 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2012 | 52 | 0.100 |
Why?
|
| Adult | 16 | 2013 | 21379 | 0.100 |
Why?
|
| HLA-DR Antigens | 2 | 2010 | 41 | 0.100 |
Why?
|
| Bone Density | 2 | 2010 | 159 | 0.100 |
Why?
|
| Pharmacists | 1 | 2012 | 125 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2012 | 186 | 0.100 |
Why?
|
| Middle Aged | 16 | 2014 | 21119 | 0.090 |
Why?
|
| Rheumatoid Factor | 2 | 2010 | 21 | 0.090 |
Why?
|
| Registries | 2 | 2014 | 730 | 0.090 |
Why?
|
| Rheumatoid Nodule | 1 | 2010 | 3 | 0.090 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2010 | 9 | 0.090 |
Why?
|
| STAT4 Transcription Factor | 1 | 2010 | 12 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 614 | 0.090 |
Why?
|
| Rectus Abdominis | 1 | 2010 | 9 | 0.090 |
Why?
|
| RANK Ligand | 1 | 2010 | 73 | 0.090 |
Why?
|
| Urinary Bladder Fistula | 1 | 2010 | 9 | 0.090 |
Why?
|
| Health Behavior | 1 | 2014 | 458 | 0.090 |
Why?
|
| Radiography | 4 | 2014 | 572 | 0.090 |
Why?
|
| Cadaver | 1 | 2010 | 136 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 25 | 0.080 |
Why?
|
| Scleroderma, Diffuse | 1 | 2008 | 25 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 230 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 766 | 0.080 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 74 | 0.080 |
Why?
|
| Cyanoacrylates | 1 | 2007 | 8 | 0.080 |
Why?
|
| Circumcision, Male | 1 | 2007 | 12 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 17 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.080 |
Why?
|
| Eosinophils | 1 | 2007 | 60 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2007 | 117 | 0.070 |
Why?
|
| Child | 5 | 2013 | 6401 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 129 | 0.070 |
Why?
|
| Skin | 2 | 2008 | 451 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 292 | 0.070 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2006 | 28 | 0.070 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.070 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2007 | 110 | 0.070 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 219 | 0.070 |
Why?
|
| Infant | 4 | 2013 | 2891 | 0.070 |
Why?
|
| Dermis | 2 | 2004 | 29 | 0.070 |
Why?
|
| Disease Progression | 4 | 2010 | 1037 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2005 | 30 | 0.060 |
Why?
|
| Amniotic Fluid | 1 | 2004 | 30 | 0.060 |
Why?
|
| Dextrans | 1 | 2004 | 33 | 0.060 |
Why?
|
| Ureter | 1 | 2004 | 16 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2004 | 14 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 232 | 0.060 |
Why?
|
| Peritoneal Dialysis | 1 | 2004 | 30 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 164 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2004 | 56 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 384 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 29 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2003 | 47 | 0.060 |
Why?
|
| Genotype | 3 | 2010 | 785 | 0.060 |
Why?
|
| Aged | 8 | 2013 | 14842 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2003 | 103 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2003 | 63 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2004 | 206 | 0.050 |
Why?
|
| Adolescent | 4 | 2010 | 8904 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2004 | 120 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 146 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2002 | 19 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 786 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 1549 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 250 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2013 | 3187 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 365 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2014 | 880 | 0.040 |
Why?
|
| Insulin | 1 | 2003 | 617 | 0.040 |
Why?
|
| Prevalence | 3 | 2009 | 1609 | 0.040 |
Why?
|
| Lung | 1 | 2004 | 849 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 2 | 2010 | 21 | 0.040 |
Why?
|
| Peptides, Cyclic | 2 | 2010 | 35 | 0.040 |
Why?
|
| Risk Factors | 4 | 2013 | 5720 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2334 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1054 | 0.040 |
Why?
|
| Logistic Models | 2 | 2014 | 1419 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2002 | 283 | 0.040 |
Why?
|
| United States | 4 | 2014 | 7338 | 0.040 |
Why?
|
| Abdominal Cavity | 1 | 2016 | 3 | 0.030 |
Why?
|
| Urinary Tract | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2008 | 2673 | 0.030 |
Why?
|
| Reference Values | 2 | 2006 | 579 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 346 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 108 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 71 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2008 | 1738 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2013 | 16 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 1860 | 0.030 |
Why?
|
| Penis | 1 | 2013 | 25 | 0.030 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 9 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2012 | 17 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2356 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1663 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 546 | 0.030 |
Why?
|
| Medical Order Entry Systems | 1 | 2012 | 24 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 453 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 330 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2012 | 64 | 0.030 |
Why?
|
| North Carolina | 1 | 2012 | 224 | 0.030 |
Why?
|
| Drug Costs | 1 | 2012 | 87 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1745 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 113 | 0.020 |
Why?
|
| Receptors, CCR6 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 7 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 5 | 0.020 |
Why?
|
| Hand Joints | 1 | 2010 | 1 | 0.020 |
Why?
|
| Foot Joints | 1 | 2010 | 6 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 281 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 188 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2012 | 344 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 378 | 0.020 |
Why?
|
| Foot | 1 | 2010 | 66 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 772 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 216 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 129 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 659 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 241 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2009 | 45 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 271 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 174 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 328 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 711 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 41 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2007 | 43 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2007 | 87 | 0.020 |
Why?
|
| Epitopes | 1 | 2008 | 146 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 57 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 475 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 411 | 0.020 |
Why?
|
| Health Status | 1 | 2009 | 429 | 0.020 |
Why?
|
| Citrulline | 1 | 2006 | 9 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 249 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 700 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 140 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 539 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 1425 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 83 | 0.020 |
Why?
|
| Vitamin D | 1 | 2009 | 516 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2004 | 60 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2004 | 66 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2004 | 2689 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 2265 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 455 | 0.010 |
Why?
|
| Acetophenones | 1 | 2003 | 12 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2003 | 12 | 0.010 |
Why?
|
| Benzopyrans | 1 | 2003 | 21 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 216 | 0.010 |
Why?
|
| Proline | 1 | 2003 | 52 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1582 | 0.010 |
Why?
|
| Selenium | 1 | 2003 | 36 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2003 | 76 | 0.010 |
Why?
|
| Transferrin | 1 | 2003 | 94 | 0.010 |
Why?
|
| Calcium Oxalate | 1 | 2002 | 2 | 0.010 |
Why?
|
| Citrates | 1 | 2002 | 7 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1753 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 304 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1293 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2003 | 270 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 134 | 0.010 |
Why?
|
| Magnesium | 1 | 2002 | 110 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 175 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 946 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 261 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 770 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 4843 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2002 | 493 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3256 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 20880 | 0.010 |
Why?
|